Mylan Laboratories Inc. reported that the US District Court for the Western District of Pennsylvania has entered judgment in favour of Napro BioTherapeutics, Inc. and Faulding Pharmaceutical Co. in the patent infringement suit regarding Mylan's paclitaxel product.

Mylan vice chairman and CEO, Robert J Coury stated, "Mylan historically has had a very small share of the paclitaxel market and as such its contribution to our sales has been de minimis. That being said, we disagree with the court's rulings and intend to file an appeal with the Federal Circuit." A May 2004 trial date has been set to rule on damages in the case.

Mylan Laboratories Inc. is a leading pharmaceutical company with four subsidiaries, Mylan Pharmaceuticals Inc., Mylan Technologies Inc., UDL Laboratories Inc. and Bertek Pharmaceuticals Inc. that develop, manufacture and market an extensive line of generic and proprietary products.